Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure

Eur Heart J. 2022 Aug 14;43(31):2994-2996. doi: 10.1093/eurheartj/ehac304.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Benzhydryl Compounds
  • Glucosides
  • Heart Failure* / drug therapy
  • Humans
  • Hyperkalemia* / chemically induced
  • Potassium
  • Sodium-Glucose Transporter 2 Inhibitors* / pharmacology
  • Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

  • Benzhydryl Compounds
  • Glucosides
  • Sodium-Glucose Transporter 2 Inhibitors
  • empagliflozin
  • Potassium